Nanobiotix announced significant advancements for its Curadigm Nanoprimer platform on November 13, 2025, including new patent filings and promising preclinical data that could reshape how intravenous therapeutics are delivered to patients. The late-stage clinical biotechnology company is positioning the platform as both a proprietary development opportunity and a collaboration hub for external partners.
Patent Portfolio Expansion Strengthens Platform Foundation
The company filed four new patent applications to expand intellectual property protection for the Curadigm platform and several potential product applications. These filings build upon Nanobiotix's existing portfolio of more than 25 umbrella patents across three nanotechnology platforms, aiming to support both internal pipeline development and external collaborations.
"We believe the Curadigm Nanoprimer platform has broad potential to redefine the way drugs can be designed and developed," said Laurent Levy, Chief Executive Officer and Chairman of the Executive Board at Nanobiotix. "Our new patent applications aim to further strengthen Curadigm's intellectual property foundation as both a collaboration platform and as the backbone of a proprietary product pipeline developed internally."
Breakthrough Preclinical Data Demonstrates Enhanced Vaccine Efficacy
At the 2025 Partnership Opportunities in Drug Delivery conference (PODD), Nanobiotix presented compelling in vivo preclinical data evaluating the Nanoprimer in combination with nucleic acid-based and peptide-based therapeutic vaccines. Julie Devalliere, PhD, Nanobiotix Senior Biologist, presented findings titled "Nanoprimer Technology for Enhanced Therapeutic Delivery: Outsmarting the Liver Barrier."
Key findings from the preclinical studies included boosted acute immune response following vaccination with mRNA lipoplex vaccines, improved memory immune response with mRNA lipoplex vaccines, and similar positive results observed with peptide-based vaccines. These data establish a new potential pathway for IV-administered therapeutic vaccines across multiple therapeutic areas, including oncology.
"Extrahepatic delivery is a persistent barrier that has prevented potentially gamechanging therapies from improving outcomes for patients in need," said Matthieu Germain, Head of the Curadigm platform at Nanobiotix. "The new therapeutic vaccine combo data presented at PODD 2025 supports our hypothesis that the Curadigm Nanoprimer could bring a novel approach to unlocking new pathways for IV-administered peptide-based and nucleic acid-based product candidates."
Addressing Universal Drug Delivery Challenges
The Curadigm Nanoprimer is designed to tackle one of modern medicine's most persistent challenges: effective extrahepatic delivery of innovative therapeutic agents administered intravenously, including RNA-based vaccines, peptide-based vaccines, and oncolytic viruses. Built from precisely engineered lipid-based nanoparticles, the Nanoprimer transiently occupies liver pathways responsible for therapeutic clearance.
This mechanism enables a greater fraction of subsequently administered therapeutic agents to reach their intended target tissues, potentially improving efficacy while reducing liver-related toxicity. The platform is designed for use in combination with IV therapeutics across multiple drug classes, potentially increasing drug bioavailability or decreasing unintended off-target effects in the liver.
Strategic Collaborations and Manufacturing Progress
Nanobiotix is actively pursuing collaboration pathways and currently has numerous material transfer agreements in place with biotechnology and pharmaceutical partners conducting exploratory evaluations of Nanoprimer combinations. The company expects the platform to function as a significant driver of long-term growth through both proprietary internal development and external partnerships.
Chemistry, Manufacturing, and Controls (CMC) activities for the Curadigm Nanoprimer are progressing in alignment with the company's development roadmap for both internal pipeline and external collaborations. These manufacturing preparations support the dual strategy of building an internal proprietary pipeline while enabling strategic partnerships.
The findings presented at PODD 2025 will serve as the foundation for Nanobiotix's initial proprietary pipeline of Nanoprimer products, marking a significant milestone in the platform's development trajectory. With potential applications across several therapeutic areas, the Curadigm Nanoprimer is positioned to address unmet medical needs while creating new pathways for innovative therapeutic delivery.
